Screener
Syndax Pharmaceuticals SNDX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
FAQ
- What is Syndax Pharmaceuticals's EPS (diluted)?
- Syndax Pharmaceuticals (SNDX) reported EPS (diluted) of -$0.48 in Q1 2026.
- How has Syndax Pharmaceuticals's EPS (diluted) changed year-over-year?
- Syndax Pharmaceuticals's EPS (diluted) increased by 51.0% year-over-year, from -$0.98 to -$0.48.
- What is the long-term trend for Syndax Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's EPS (diluted) has grown at a 63.5% compound annual growth rate (CAGR), from $0.46 to -$3.29.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Syndax Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude